| Not Yet Recruiting | Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia NCT06446661 | University of Chicago | N/A |
| Not Yet Recruiting | HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hema NCT07175415 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Resid NCT07192237 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell NCT07498465 | Children's Oncology Group | Phase 1 |
| Not Yet Recruiting | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592 | Washington University School of Medicine | — |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Recruiting | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity NCT07228741 | St. Jude Children's Research Hospital | Phase 2 |
| Not Yet Recruiting | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL NCT07454226 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Manage NCT05621291 | National Cancer Institute (NCI) | N/A |
| Not Yet Recruiting | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adult NCT07328503 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | ALL Backbone in AYAs NCT07227584 | Dana-Farber Cancer Institute | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Pos NCT07387926 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Not Yet Recruiting | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors NCT07483749 | The Children's Hospital of Zhejiang University School of Medicine | — |
| Not Yet Recruiting | Treatment for Ph-negative ALL for Adults up to 65 Years NCT07443592 | PETHEMA Foundation | N/A |
| Recruiting | Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Pr NCT07325305 | Murdoch Childrens Research Institute | N/A |
| Recruiting | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia NCT07400029 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403 | King Hussein Cancer Center | N/A |
| Enrolling By Invitation | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acut NCT07515430 | Sun Yat-sen University | — |
| Recruiting | A Study of Revumenib and Mezigdomide in People With Leukemia NCT07356154 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase NCT07320534 | Gadjah Mada University | Phase 4 |
| Withdrawn | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participan NCT05521087 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoie NCT07479927 | Hospital Universitario La Paz | N/A |
| Not Yet Recruiting | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukem NCT07301138 | Ruijin Hospital | Phase 2 |
| Recruiting | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies NCT07284927 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia NCT07295951 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL NCT07203352 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Recruiting | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients W NCT05751044 | Princess Maxima Center for Pediatric Oncology | Phase 1 / Phase 2 |
| Recruiting | The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Tre NCT07203742 | Ege University | N/A |
| Recruiting | Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemi NCT03932903 | Northwestern University | N/A |
| Recruiting | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible NCT07072494 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL NCT07066397 | TriArm Therapeutics (Taiwan) Limited | Phase 1 |
| Recruiting | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid NCT06287944 | City of Hope Medical Center | Phase 1 |
| Recruiting | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoieti NCT06735690 | City of Hope Medical Center | EARLY_Phase 1 |
| Recruiting | CAYA Cancer Retrospective Cohort Study NCT07246213 | Resonance, Inc. | — |
| Recruiting | Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematolog NCT07016165 | Gadjah Mada University | Phase 4 |
| Withdrawn | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant NCT05968170 | Neena Kapoor, M.D. | N/A |
| Recruiting | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia NCT06847269 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy NCT06985485 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoieti NCT06860269 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Recruiting | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphobl NCT06777979 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies NCT06894693 | Guangdong Ruishun Biotech Co., Ltd | Phase 1 |
| Recruiting | Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise NCT05025774 | Masonic Cancer Center, University of Minnesota | — |
| Recruiting | Newly-diagnosed Pediatric T-cell ALL Protocol NCT06855810 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 / Phase 3 |
| Recruiting | MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence NCT06323044 | Roswell Park Cancer Institute | N/A |
| Recruiting | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Le NCT06816134 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma NCT06533748 | St. Jude Children's Research Hospital | Phase 2 |
| Not Yet Recruiting | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 NCT06777264 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Effects of Core Stabilization Exercises in Children with Acute Lymphoblastic Leukemia NCT06794762 | Karamanoğlu Mehmetbey University | N/A |
| Recruiting | Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL NCT06886074 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Recruiting | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemi NCT06289673 | St. Jude Children's Research Hospital | Phase 4 |
| Recruiting | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 NCT06718244 | Ruijin Hospital | Phase 2 |
| Recruiting | Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant NCT06575296 | City of Hope Medical Center | Phase 1 |
| Suspended | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home NCT06639958 | Children's Oncology Group | N/A |
| Recruiting | Early Assessment of Cardiac Function After Treatment With CAR-T Cells NCT06350994 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relap NCT06452732 | Peking University People's Hospital | — |
| Not Yet Recruiting | Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia NCT06674850 | Assiut University | — |
| Recruiting | Raman Spectroscopy Compared to Flow Cytometry NCT06291428 | Hospital Regional de Alta Especialidad del Bajio | — |
| Recruiting | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. NCT06752785 | Guangzhou Women and Children's Medical Center | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias NCT06364423 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia NCT04322084 | St. Jude Children's Research Hospital | — |
| Recruiting | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Tr NCT05589896 | Ossium Health, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Pos NCT06308588 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and NCT06128070 | City of Hope Medical Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Recruiting | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Child NCT06756152 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Not Yet Recruiting | the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leuke NCT06461091 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Recruiting | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT NCT06477549 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | PTCy and ATG for MSD and MUD Transplants NCT06299462 | Instituto Nacional de Cancer, Brazil | Phase 1 / Phase 2 |
| Recruiting | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leu NCT06195891 | City of Hope Medical Center | Phase 1 |
| Recruiting | Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. NCT06659653 | Tan Jie | EARLY_Phase 1 |
| Recruiting | Vitamin A and D Supplementation in Allogeneic HCT NCT06508099 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Re NCT06393335 | The Children's Hospital of Zhejiang University School of Medicine | EARLY_Phase 1 |
| Recruiting | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies NCT06408194 | Stanford University | Phase 1 |
| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density NCT06367725 | University of Aarhus | — |
| Recruiting | Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO NCT06025682 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients NCT05963971 | Columbia University | N/A |
| Recruiting | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen R NCT05887167 | Joshua Sasine, MD, PhD | Phase 1 |
| Not Yet Recruiting | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia NCT06242353 | Karolinska University Hospital | — |
| Recruiting | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refract NCT06227026 | University of Utah | Phase 1 |
| Unknown | The Role of NK Cells to Detect Blood Infection in ALL. NCT06160115 | Assiut University | — |
| Recruiting | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patient NCT06220487 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855 | University of Colorado, Denver | Phase 1 |
| Withdrawn | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute NCT04845035 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT06144606 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy Evaluation of Next-generation CD19-UCART NCT05381181 | Bioray Laboratories | Phase 1 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Child NCT06475820 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Withdrawn | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory L NCT05321940 | Juan C. Ramos, MD | Phase 1 |
| Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies NCT05541341 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Hepatoprotective Measures for Children at High Risk of NAFLD NCT06918080 | Ain Shams University | Phase 4 |
| Recruiting | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia NCT06918054 | Ain Shams University | Phase 4 |
| Unknown | Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation NCT06125106 | Zhejiang University | Phase 1 |
| Unknown | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidam NCT06087419 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Completed | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD NCT06093334 | University of Erlangen-Nürnberg Medical School | N/A |
| Completed | Insomnia Prevention in Children With Acute Lymphoblastic Leukemia NCT05866887 | Dana-Farber Cancer Institute | N/A |
| Completed | Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation NCT06209190 | Hospital Universitario Dr. Jose E. Gonzalez | N/A |
| Completed | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias NCT05969002 | National Cancer Institute (NCI) | — |
| Unknown | FoxO3a and PU.1 in Acute Lymphoblastic Leukemia NCT04092348 | Assiut University | — |
| Recruiting | European Prospective Investigation Into Childhood Cancer NCT05375617 | Columbia University | — |
| Recruiting | Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphobla NCT05519579 | Northside Hospital, Inc. | Phase 2 |
| Unknown | Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia NCT05639673 | Rigshospitalet, Denmark | — |
| Completed | Effects of Home-Based Exercise Program in Children After Acute Lymphoblastic Leukemia NCT06664736 | Gazi University | N/A |
| Recruiting | A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) NCT05748171 | Pfizer | Phase 2 |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) NCT05581030 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment NCT05774990 | University of Southern Denmark | — |
| Recruiting | Childhood Cancer Survivors' Affective Response to Exercise NCT05763290 | St. Jude Children's Research Hospital | — |
| Active Not Recruiting | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, a NCT05457556 | Children's Oncology Group | Phase 3 |
| Recruiting | Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia NCT05501899 | Children's Hospital of Orange County | EARLY_Phase 1 |
| Unknown | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies NCT05739227 | Xuzhou Medical University | EARLY_Phase 1 |
| Completed | A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients NCT07039383 | Novartis Pharmaceuticals | — |
| Completed | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia NCT05687032 | Pfizer | Phase 4 |
| Active Not Recruiting | A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer NCT05428176 | City of Hope Medical Center | N/A |
| Unknown | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Re NCT06277011 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Completed | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and S NCT05694364 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Withdrawn | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia NCT05168748 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Adaptive Variable-Resistance Training in Pediatric Survivors of Acute Lymphoblastic Leukemia NCT06338020 | Cairo University | N/A |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Le NCT05327894 | Princess Maxima Center for Pediatric Oncology | Phase 3 |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Recruiting | A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) NCT05579132 | MSD R&D (China) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort NCT05929976 | Columbia University | — |
| Terminated | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers NCT04083170 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | CAV Regimen for R/R Ph- B-ALL NCT05657652 | The First Affiliated Hospital of Soochow University | N/A |
| Unknown | Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leu NCT05950204 | Coordinación de Investigación en Salud, Mexico | N/A |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Recruiting | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies NCT05618041 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Withdrawn | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies NCT04282174 | Baptist Health South Florida | Phase 2 |
| Completed | Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence NCT05587582 | Roswell Park Cancer Institute | — |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibito NCT05515029 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Recruiting | Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL NCT05811845 | IRCCS Burlo Garofolo | — |
| Terminated | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia NCT05410574 | Washington University School of Medicine | N/A |
| Completed | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia NCT05563545 | Shanghai Simnova Biotechnology Co.,Ltd. | Phase 1 |
| Active Not Recruiting | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Trea NCT05139004 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CA NCT05037669 | University of Pennsylvania | Phase 1 |
| Active Not Recruiting | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia ( NCT05386576 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients W NCT05268003 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) NCT03768310 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Ac NCT03399773 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Pat NCT05433532 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With NCT04726241 | PedAL BCU, LLC | Phase 1 / Phase 2 |
| Recruiting | Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients NCT06392581 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Recruiting | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or M NCT04872478 | Meryx, Inc. | Phase 1 |
| Recruiting | The Patient Cohort of the National Center for Precision Medicine in Leukemia NCT05326919 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States NCT04928599 | Children's Oncology Group | — |
| Completed | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516 | Syndax Pharmaceuticals | Phase 1 |
| Unknown | To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B- NCT05223686 | Hrain Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823 | Chongqing Precision Biotech Co., Ltd | Phase 2 |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Unknown | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSC NCT05809167 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL NCT05578378 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Unknown | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL NCT05252403 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 2 |
| Unknown | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia NCT05133310 | Hospital General de Mexico | Phase 4 |
| Active Not Recruiting | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector C NCT04975555 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Completed | How Effective is the Dose-graded Aerobic Training in Children Survivors of Acute Lymphoblastic Leukemia? NCT05679817 | Cairo University | N/A |
| Not Yet Recruiting | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-r NCT05054465 | Israeli Medical Association | Phase 1 / Phase 2 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings NCT04969601 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Unknown | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT NCT04764513 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | Backtracking Leukemia-Typical Somatic Mutations in Cord Blood NCT05014165 | Children's Oncology Group | — |
| Terminated | SPARK-ALL: Calaspargase Pegol in Adults With ALL NCT04817761 | Institut de Recherches Internationales Servier | Phase 2 / Phase 3 |
| Active Not Recruiting | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test NCT04635384 | CareDx | — |
| Terminated | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies NCT04762875 | Ensoma | Phase 2 |
| Completed | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients NCT04956666 | Institut de Recherches Internationales Servier | Phase 2 |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) NCT04811560 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Completed | A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the T NCT04954326 | Institut de Recherches Internationales Servier | Phase 2 |
| Active Not Recruiting | huCART19-IL18 in CD19+ Cancers NCT04684563 | University of Pennsylvania | Phase 1 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Active Not Recruiting | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies NCT04732845 | Benjamin Tomlinson | Phase 1 |
| Completed | TDM of Asparaginase in ALL2008 NCT04843514 | Aarhus University Hospital | — |
| Unknown | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors NCT04814004 | Kai Lin Xu; Jun Nian Zheng | Phase 1 |
| Unknown | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignanci NCT04796688 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Active Not Recruiting | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML NCT04787263 | Bambino Gesù Hospital and Research Institute | Phase 1 / Phase 2 |
| Suspended | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin ( NCT04747912 | University of Chicago | Phase 2 |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Unknown | Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leuke NCT05326984 | Hospital General de Mexico | N/A |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myelo NCT04095858 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Unknown | Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute NCT04677231 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Ma NCT04689204 | He Huang | EARLY_Phase 1 |
| Active Not Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study NCT04537871 | City of Hope Medical Center | — |
| Active Not Recruiting | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia NCT04606433 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malig NCT04532281 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematologic NCT04532203 | Zhejiang University | EARLY_Phase 1 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Terminated | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acut NCT04225676 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL NCT04049383 | Medical College of Wisconsin | Phase 1 |
| Unknown | Assesment of JL1 Expression in Acute Leukemia NCT04554381 | Assiut University | Phase 1 |
| Completed | Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precur NCT04524455 | Amgen | Phase 1 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Completed | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 NCT04452604 | French Innovative Leukemia Organisation | — |
| Unknown | Clinical Significance of Occult Central Nervous System Localization NCT05772000 | University of Rome Tor Vergata | — |
| Unknown | Vitamin D and Methotrexate Adverse Effects NCT04488237 | Assiut University | — |
| Recruiting | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-ce NCT04532268 | Zhejiang University | EARLY_Phase 1 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Completed | Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL NCT06195735 | Aarhus University Hospital | — |
| Active Not Recruiting | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I NCT04233346 | Otsuka Beijing Research Institute | Phase 2 |
| Completed | Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study NCT04843150 | Aarhus University Hospital | — |
| Completed | Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 NCT04825548 | Aarhus University Hospital | — |
| Terminated | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL) NCT03668392 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Withdrawn | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Ly NCT03628053 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Study of Sequential CAR-T Cell Treating Leukemia Children NCT04340154 | Beijing Boren Hospital | Phase 2 |
| Completed | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children NCT04340167 | Beijing Boren Hospital | Phase 2 |
| Active Not Recruiting | Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymph NCT04329325 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Completed | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML NCT04151706 | Robert Lowsky | Phase 2 |
| Active Not Recruiting | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Pat NCT04262843 | City of Hope Medical Center | Phase 2 |
| Unknown | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignanc NCT04226989 | He Huang | EARLY_Phase 1 |
| Recruiting | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-tran NCT03533816 | University of Kansas Medical Center | Phase 1 |
| Recruiting | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or So NCT03934372 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Recruiting | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Mal NCT04227015 | He Huang | EARLY_Phase 1 |
| Unknown | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL NCT04168788 | University Hospital, Angers | N/A |
| Completed | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lympho NCT04145531 | Jazz Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy NCT04014764 | Notable Labs | — |
| Completed | Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) NCT04007601 | St. Jude Children's Research Hospital | N/A |
| Unknown | CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia NCT04154709 | Kai Lin Xu; Jun Nian Zheng | Phase 1 |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjuga NCT03898128 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Recruiting | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults NCT04179929 | PETHEMA Foundation | N/A |
| Recruiting | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukem NCT03970096 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic L NCT04105530 | St. Jude Children's Research Hospital | N/A |
| Unknown | A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells NCT04158011 | Sheba Medical Center | — |
| Recruiting | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation NCT04065399 | Syndax Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolesce NCT04888468 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Effect of Vitamin D Diffiency on Oral Mucosa in Patients Recieving Methotrexate Chemotherapy NCT04096846 | Assiut University | — |
| Terminated | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Tra NCT03856216 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic NCT04067518 | Institut de Recherches Internationales Servier | Phase 2 |
| Recruiting | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies NCT03765177 | Ottawa Hospital Research Institute | Phase 1 / Phase 2 |
| Unknown | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL NCT04206943 | Acibadem University | Phase 1 / Phase 2 |
| Completed | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia NCT03964259 | Virginia Commonwealth University | Phase 1 |
| Unknown | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cel NCT03887156 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Recruiting | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia NCT04067336 | Kura Oncology, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial NCT03844048 | AbbVie | Phase 3 |
| Unknown | Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Ch NCT04364451 | Aristotle University Of Thessaloniki | — |
| Recruiting | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) P NCT03919526 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic NCT03860844 | Sanofi | Phase 2 |
| Unknown | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies NCT04007978 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Withdrawn | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Underg NCT03187691 | Matinas BioPharma Nanotechnologies, Inc. | Phase 2 |
| Completed | Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic Leukemia NCT04015882 | Bezmialem Vakif University | N/A |
| Completed | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eli NCT03677596 | Pfizer | Phase 4 |
| Active Not Recruiting | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL NCT03960840 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) NCT03904134 | Center for International Blood and Marrow Transplant Research | N/A |
| Withdrawn | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab NCT03982992 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Recruiting | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia NCT03571321 | University of Chicago | Phase 1 |
| Unknown | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malign NCT04008251 | Wuhan Sian Medical Technology Co., Ltd | Phase 1 |
| Terminated | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia NCT03913559 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia NCT03318770 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Nutritional Status in Children With ALL in Guatemala NCT03471416 | Columbia University | — |
| Unknown | CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients NCT03902197 | Xuanwu Hospital, Beijing | Phase 2 |
| Recruiting | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies NCT03802695 | Orca Biosystems, Inc. | Phase 1 |
| Unknown | Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia NCT03798509 | Hrain Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT NCT03810196 | Children's Hospital of Philadelphia | N/A |
| Completed | Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL NCT03792633 | University of Pennsylvania | Phase 2 |
| Active Not Recruiting | MT2017-45: CAR-T Cell Therapy for Heme Malignancies NCT03642626 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan NCT03821610 | University of Birmingham | Phase 2 |
| Completed | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 NCT03555955 | Jazz Pharmaceuticals | Phase 1 |
| Completed | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia NCT03575325 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Ma NCT03581045 | St. Jude Children's Research Hospital | — |
| Unknown | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation NCT03655145 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Suspended | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treatin NCT03494569 | City of Hope Medical Center | Phase 1 |
| Terminated | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia NCT03742323 | PETHEMA Foundation | Phase 1 / Phase 2 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Recruiting | Pharmacogenomics of Asparaginase Induced Hepatotoxicity NCT03568266 | University of Southern California | — |
| Terminated | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic NCT03705507 | University of Birmingham | Phase 1 / Phase 2 |
| Terminated | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirub NCT03564678 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients NCT03422731 | City of Hope Medical Center | EARLY_Phase 1 |
| Active Not Recruiting | Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residu NCT03441061 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Anti-mullerian Hormone in Acute Lymphoblastic Leukemia NCT05793463 | IRCCS Burlo Garofolo | — |
| Active Not Recruiting | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children Wit NCT03178617 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Posit NCT03147612 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation NCT03434730 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia NCT03429387 | Peter MacCallum Cancer Centre, Australia | N/A |
| Terminated | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab NCT03286114 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia NCT03204916 | Children's Oncology Group | — |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Unknown | New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia NCT03249636 | Assiut University | — |
| Recruiting | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentica NCT02999854 | Kiadis Pharma | Phase 3 |
| Unknown | Dependence Receptors and Leukemia NCT03278145 | Hospices Civils de Lyon | — |
| Unknown | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma NCT03298828 | Third Military Medical University | Phase 1 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-pre NCT03476239 | Amgen | Phase 3 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transpla NCT03267186 | Andrew Rezvani | Phase 2 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance NCT03114865 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase NCT03267030 | Birgitte Klug Albertsen | Phase 2 |